Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis
Frontiers in Hematology · 29.05.2026 · 5
DOI: 10.3389/frhem.2026.1851998 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Hematology, online erschienen am 29.05.2026. Verfasst von Mohamed M. Khamis und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
High-risk acute promyelocytic leukemia (APL) [white blood cell (WBC) count >10 × 10 9 /L) accounts for 20%–30% of cases with early mortality of 15%–25%. Optimal induction with reduced-intensity all- trans retinoic acid plus arsenic trioxide (ATRA+ATO) versus intensive chemotherapy remains debated.
Methods
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO CRD420261293473), we searched PubMed and Cochrane Library (2000–2025). Reduced-intensity: ATRA+ATO with gemtuzumab ozogamicin (GO; 6–9 mg/m 2 ), low-dose idarubicin (one to two doses of 12 mg/m 2 ), or hydroxyurea; intensive: ATRA-based therapy with three or more anthracycline doses. Random-effects meta-analysis used logit transformation and inverse variance weighting. RoB 2 and ROBINS-I were used to assess risk of bias.
Results
A total of 17 studies (1,323 patients, 11 on the reduced-intensity arm and 14 on the intensive arm) were included. Complete remission (CR) was 92.3% (95%CI = 85.9–95.9%, I 2 = 0%) versus 89.3% (82.6%–93.6%, I 2 = 56%, p = 0.35). Early mortality was 8.8% versus 10.4% ( p = 0.62). Event-free survival (EFS) from two randomized controlled trials (RCTs) favored reduced-intensity induction (HR = 0.23, 95%CI= 0.07–0.76, p = 0.015). Relapse was 3.9% versus 5.5% ( p = 0.49). WBC-stratified CR remained stable at 91.6%–92.5% with reduced-intensity induction, while intensive CR declined from 96.0% to 86.6% at WBC ≥30 × 10 9 /L.
Conclusions
Reduced-intensity ATRA+ATO-based induction achieves equivalent CR, comparable early mortality, superior EFS (HR = 0.23, p = 0.015), and lower relapse, supporting ATRA+ATO with GO or low-dose anthracycline as the preferred first-line therapy for high-risk APL. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420261293473.
Zitieren
APA
Khamis, M. M., Rodriguez, N. A. G., & Kunwor, R. (2026). Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis. Frontiers in Hematology, 5. https://doi.org/10.3389/frhem.2026.1851998
Vancouver
Khamis MM, Rodriguez NAG, Kunwor R. Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis. Frontiers in Hematology. 2026;5. doi:10.3389/frhem.2026.1851998
BibTeX
@article{Khamis2026,
author = {Khamis, Mohamed M. and Rodriguez, Nehemias Antonio Guevara and Kunwor, Ranju},
title = {Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis},
journal = {Frontiers in Hematology},
year = {2026},
volume = {5},
doi = {10.3389/frhem.2026.1851998}
}
EUVIMED